GPRACR: A Non-Coding RNA Molecule Regulating GPR107 (G401554)

Target Name: GPRACR

NCBI ID: G401554

GPRACR

Other Name(s): GPR107 adjacent cis regulating lncRNA | LncGPR107

GPRACR: A Non-Coding RNA Molecule Regulating GPR107

GPRACR (GPR107 adjacent cis-regulating lncRNA) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is located adjacent to the G protein-coupled receptor GPR107 and is involved in the regulation of gene expression.

GPRACR is a small non-coding RNA molecule that has been shown to play a role in the regulation of gene expression. It is located adjacent to the G protein-coupled receptor GPR107 and is involved in the regulation of gene expression. The G protein-coupled receptor is a transmembrane protein that is involved in the regulation of many cellular processes, including sensory perception, neurotransmission, and signaling pathways.

GPRACR is thought to function as a negative regulator of GPR107. This means that when GPR107 is activated, GPRACR is inhibited, and when GPR107 is inhibited, GPRACR is activated. This interaction between GPR107 and GPRACR is important for the regulation of cellular processes that involve the G protein-coupled receptor.

GPRACR has been shown to play a role in the regulation of many cellular processes, including cell growth, differentiation, and apoptosis. For example, GPRACR has been shown to be involved in the regulation of cell growth and has been shown to play a role in the development of cancer.

In addition to its role in the regulation of GPR107, GPRACR has also been shown to have potential as a drug target or biomarker. One way to study the potential of GPRACR as a drug target is to use RNA interference techniques to knockdown the expression of GPRACR in cancer cells. This would allow researchers to study the effects of inhibiting GPRACR on the growth and survival of cancer cells.

Another way to study the potential of GPRACR as a drug target is to use GPRACR-specific small interfering RNA (siRNA) to treat cancer cells. This would allow researchers to study the effects of administering GPRACR to cancer cells and to determine the effectiveness of GPRACR as a drug.

GPRACR has also been shown to be a potential biomarker for cancer. The expression of GPRACR has been shown to be elevated in many types of cancer, including breast, lung, and ovarian cancer. This suggests that GPRACR may be a useful biomarker for cancer and could be used in the development of new cancer therapies.

In conclusion, GPRACR is a non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and is located adjacent to the G protein-coupled receptor GPR107. It is thought to function as a negative regulator of GPR107 and has been shown to play a role in the regulation of many cellular processes, including cell growth, differentiation, and apoptosis. In addition to its role in the regulation of GPR107, GPRACR has also been shown to have potential as a drug target or biomarker. Further research is needed to fully understand the role of GPRACR in cellular processes and its potential as a drug target or biomarker.

Protein Name: GPR107 Adjacent Cis Regulating LncRNA

The "GPRACR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPRACR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets